These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 29444985)

  • 1. Molecular Pharmacodynamics-Guided Scheduling of Biologically Effective Doses: A Drug Development Paradigm Applied to MET Tyrosine Kinase Inhibitors.
    Srivastava AK; Hollingshead MG; Govindharajulu JP; Covey JM; Liston D; Simpson MA; Peggins JO; Bottaro DP; Wright JJ; Kinders RJ; Doroshow JH; Parchment RE
    Mol Cancer Ther; 2018 Mar; 17(3):698-709. PubMed ID: 29444985
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacodynamic Response of the MET/HGF Receptor to Small-Molecule Tyrosine Kinase Inhibitors Examined with Validated, Fit-for-Clinic Immunoassays.
    Srivastava AK; Hollingshead MG; Weiner J; Navas T; Evrard YA; Khin SA; Ji JJ; Zhang Y; Borgel S; Pfister TD; Kinders RJ; Bottaro DP; Linehan WM; Tomaszewski JE; Doroshow JH; Parchment RE
    Clin Cancer Res; 2016 Jul; 22(14):3683-94. PubMed ID: 27001313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overexpression of PI3K p110α contributes to acquired resistance to MET inhibitor, in MET-amplified SNU-5 gastric xenografts.
    Ji F; Liu X; Wu Y; Fang X; Huang G
    Drug Des Devel Ther; 2015; 9():5697-704. PubMed ID: 26543351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Foretinib (GSK1363089), a multi-kinase inhibitor of MET and VEGFRs, inhibits growth of gastric cancer cell lines by blocking inter-receptor tyrosine kinase networks.
    Kataoka Y; Mukohara T; Tomioka H; Funakoshi Y; Kiyota N; Fujiwara Y; Yashiro M; Hirakawa K; Hirai M; Minami H
    Invest New Drugs; 2012 Aug; 30(4):1352-60. PubMed ID: 21655918
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Foretinib (GSK1363089), an orally available multikinase inhibitor of c-Met and VEGFR-2, blocks proliferation, induces anoikis, and impairs ovarian cancer metastasis.
    Zillhardt M; Park SM; Romero IL; Sawada K; Montag A; Krausz T; Yamada SD; Peter ME; Lengyel E
    Clin Cancer Res; 2011 Jun; 17(12):4042-51. PubMed ID: 21551255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tepotinib Inhibits the Epithelial-Mesenchymal Transition and Tumor Growth of Gastric Cancers by Increasing GSK3β, E-Cadherin, and Mucin 5AC and 6 Levels.
    Sohn SH; Sul HJ; Kim B; Kim BJ; Kim HS; Zang DY
    Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32825724
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CT-707, a Novel FAK Inhibitor, Synergizes with Cabozantinib to Suppress Hepatocellular Carcinoma by Blocking Cabozantinib-Induced FAK Activation.
    Wang DD; Chen Y; Chen ZB; Yan FJ; Dai XY; Ying MD; Cao J; Ma J; Luo PH; Han YX; Peng Y; Sun YH; Zhang H; He QJ; Yang B; Zhu H
    Mol Cancer Ther; 2016 Dec; 15(12):2916-2925. PubMed ID: 27638856
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer.
    Shah MA; Wainberg ZA; Catenacci DV; Hochster HS; Ford J; Kunz P; Lee FC; Kallender H; Cecchi F; Rabe DC; Keer H; Martin AM; Liu Y; Gagnon R; Bonate P; Liu L; Gilmer T; Bottaro DP
    PLoS One; 2013; 8(3):e54014. PubMed ID: 23516391
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel lead compound CM-118: antitumor activity and new insight into the molecular mechanism and combination therapy strategy in c-Met- and ALK-dependent cancers.
    Meng L; Shu M; Chen Y; Yang D; He Q; Zhao H; Feng Z; Liang C; Yu K
    Cancer Biol Ther; 2014 Jun; 15(6):721-34. PubMed ID: 24618813
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted dual inhibition of c-Met/VEGFR2 signalling by foretinib improves antitumour effects of nanoparticle paclitaxel in gastric cancer models.
    Grojean M; Schwarz MA; Schwarz JR; Hassan S; von Holzen U; Zhang C; Schwarz RE; Awasthi N
    J Cell Mol Med; 2021 Jun; 25(11):4950-4961. PubMed ID: 33939252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Establishment of patient-derived gastric cancer xenografts: a useful tool for preclinical evaluation of targeted therapies involving alterations in HER-2, MET and FGFR2 signaling pathways.
    Wang H; Lu J; Tang J; Chen S; He K; Jiang X; Jiang W; Teng L
    BMC Cancer; 2017 Mar; 17(1):191. PubMed ID: 28292264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integrating Murine and Clinical Trials with Cabozantinib to Understand Roles of MET and VEGFR2 as Targets for Growth Inhibition of Prostate Cancer.
    Varkaris A; Corn PG; Parikh NU; Efstathiou E; Song JH; Lee YC; Aparicio A; Hoang AG; Gaur S; Thorpe L; Maity SN; Bar Eli M; Czerniak BA; Shao Y; Alauddin M; Lin SH; Logothetis CJ; Gallick GE
    Clin Cancer Res; 2016 Jan; 22(1):107-21. PubMed ID: 26272062
    [TBL] [Abstract][Full Text] [Related]  

  • 13. KRC-408, a novel c-Met inhibitor, suppresses cell proliferation and angiogenesis of gastric cancer.
    Hong SW; Jung KH; Park BH; Zheng HM; Lee HS; Choi MJ; Yun JI; Kang NS; Lee J; Hong SS
    Cancer Lett; 2013 May; 332(1):74-82. PubMed ID: 23348694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Translational pharmacokinetic-pharmacodynamic modeling of preclinical and clinical data of the oral MET inhibitor tepotinib to determine the recommended phase II dose.
    Xiong W; Friese-Hamim M; Johne A; Stroh C; Klevesath M; Falchook GS; Hong DS; Girard P; El Bawab S
    CPT Pharmacometrics Syst Pharmacol; 2021 May; 10(5):428-440. PubMed ID: 33818908
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The novel ATP-competitive inhibitor of the MET hepatocyte growth factor receptor EMD1214063 displays inhibitory activity against selected MET-mutated variants.
    Medová M; Pochon B; Streit B; Blank-Liss W; Francica P; Stroka D; Keogh A; Aebersold DM; Blaukat A; Bladt F; Zimmer Y
    Mol Cancer Ther; 2013 Nov; 12(11):2415-24. PubMed ID: 24061647
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination effect of lapatinib with foretinib in HER2 and MET co-activated experimental esophageal adenocarcinoma.
    Hassan MS; Williams F; Awasthi N; Schwarz MA; Schwarz RE; Li J; von Holzen U
    Sci Rep; 2019 Nov; 9(1):17608. PubMed ID: 31772236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth.
    Yakes FM; Chen J; Tan J; Yamaguchi K; Shi Y; Yu P; Qian F; Chu F; Bentzien F; Cancilla B; Orf J; You A; Laird AD; Engst S; Lee L; Lesch J; Chou YC; Joly AH
    Mol Cancer Ther; 2011 Dec; 10(12):2298-308. PubMed ID: 21926191
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases.
    Qian F; Engst S; Yamaguchi K; Yu P; Won KA; Mock L; Lou T; Tan J; Li C; Tam D; Lougheed J; Yakes FM; Bentzien F; Xu W; Zaks T; Wooster R; Greshock J; Joly AH
    Cancer Res; 2009 Oct; 69(20):8009-16. PubMed ID: 19808973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of 3-substituted-6-(1-(1H-[1,2,3]triazolo[4,5-b]pyrazin-1-yl)ethyl)quinoline derivatives as highly potent and selective mesenchymal-epithelial transition factor (c-Met) inhibitors via metabolite profiling-based structural optimization.
    Zhao F; Zhang LD; Hao Y; Chen N; Bai R; Wang YJ; Zhang CC; Li GS; Hao LJ; Shi C; Zhang J; Mao Y; Fan Y; Xia GX; Yu JX; Liu YJ
    Eur J Med Chem; 2017 Jul; 134():147-158. PubMed ID: 28411455
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Translational pharmacokinetic-pharmacodynamic modeling from nonclinical to clinical development: a case study of anticancer drug, crizotinib.
    Yamazaki S
    AAPS J; 2013 Apr; 15(2):354-66. PubMed ID: 23250669
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.